top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance


14/04/2026











FDA Grants Fast Track to Daretabart for High‑Risk Neuroblastoma (Ref)


Renaissance Pharma's Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody, has received Fast Track status from the U.S. FDA for treating high-risk neuroblastoma (HRNB), a rare pediatric cancer


  • Clinical trial progress: The FDA has cleared the IND application, enabling the start of the SHINE Phase II/III clinical trial in relapse or refractory children with HRNB in the US



bottom of page